Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DCDS0780A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DCDS0780A Monotherapy | EXPERIMENTAL | Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first). |
| DCDS0780A + Rituximab | EXPERIMENTAL | Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m\^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first). |
| DCDS0780A + Obinutuzumab | EXPERIMENTAL | Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first). |
| Name | Type | Description |
|---|---|---|
| DCDS0780A | DRUG | Participants will receive escalating doses of DCDS0780A as intravenous infusion. |
| Rituximab | DRUG | Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion. |
| Obinutuzumab | DRUG | Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion. |
Inclusion Criteria: * Life expectancy of at least 12 weeks * Histologically confirmed B-cell non-Hodgkin's lymphoma that has relapsed after or failed to respond to at least one prior treatment regimen and for which no suitable therapy of curative intent or higher priority exists * A clinical indica...
DCDS0780A is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma, specifically in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
DCDS0780A is being developed by Roche Holding AG, a biopharmaceutical company traded on the OTC market under the ticker RHHBY. Roche is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with Non-Hodgkin's Lymphoma.
DCDS0780A is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials.
DCDS0780A has been studied in one clinical trial, identified as NCT02453087. This was a Phase 1 study of escalating doses of DCDS0780A in participants with relapsed or refractory B-cell Non-Hodgkin's Lymphoma. The trial was conducted in the United States and has been completed.
The specific molecular target of DCDS0780A has not been disclosed in available information. It is classified as a small molecule therapeutic agent, but its mechanism of action in treating Non-Hodgkin's Lymphoma has not been publicly detailed.